BARD1 and ovarian cancer: Since the molecular underpinning of BRCA-associated breast and ovarian cancers is well defined and data from a recent genome editing screening allowed us to compare variant binding data with a reliable functional HRD test in addition to ClinVar and AlphaMissense data, we examined the binding of mutated full-length BRCA1 or isolated RING and BRCT domains to BARD1 and RBBP8, respectively.